--- title: MHRA Top 10 Inspection Findings description: MHRA's top findings per chapter and E-book for download image: https://blog.pqegroup.com/hubfs/MHRA%20Top%20Pre%20Pandemic_Site%20Banner-1.jpg --- [![Logo PQE Group - azzurro - 2024](https://blog.pqegroup.com/hs-fs/hubfs/Logo%20PQE%20Group%20-%20azzurro%20-%202024.png?width=2000&height=721&name=Logo%20PQE%20Group%20-%20azzurro%20-%202024.png "Logo PQE Group - azzurro - 2024")](https://www2.pqegroup.com) - [Home](https://www2.pqegroup.com/) - [Industry](https://www2.pqegroup.com/industry/) - [Pharma & API](https://www2.pqegroup.com/pharma-api/) - [Medical Device](https://www2.pqegroup.com/medical-device/) - [Biotech](https://www2.pqegroup.com/biotech/) - [Startup](https://www2.pqegroup.com/startup/) - [Veterinary](https://www2.pqegroup.com/veterinary/) - [Services](https://www2.pqegroup.com/services/) - [Data Integrity](https://www2.pqegroup.com/data-integrity/) - [Digital Governance](https://www2.pqegroup.com/digital-governance/) - [Engineering](https://www2.pqegroup.com/engineering/) - [Commissioning, Qualification and Validation (CQV)](https://www2.pqegroup.com/commissioning-qualification-validation/) - [Quality Compliance](https://www2.pqegroup.com/quality-compliance/) - [Laboratory Excellence](https://www2.pqegroup.com/laboratory-excellence/) - [Regulatory Affairs](https://www2.pqegroup.com/regulatory-affairs/) - [Audits](https://www2.pqegroup.com/audits/) - [Training](https://www2.pqegroup.com/training/) - [Clinical Research](https://www2.pqegroup.com/clinical-research-services/) - [Pharmacovigilance](https://www2.pqegroup.com/pharmacovigilance/) - About - [About Us](https://www2.pqegroup.com/about/) - [ESG](https://www2.pqegroup.com/about/csr/) - [Women in STEM](https://www2.pqegroup.com/about/women-in-stem/) - Resources - [News & Press](https://www2.pqegroup.com/news/) - [Webinars](https://www2.pqegroup.com/webinars/) - [Blog](https://blog.pqegroup.com/) - [Careers](https://www2.pqegroup.com/careers/) - [Contact Us](https://www2.pqegroup.com/contact-us/) ![](https://blog.pqegroup.com/hubfs/blank-user.png) Florencia Paola La Selva C&Q Engineer Senior Consultant, @PQE Group # **MHRA Top 10 Inspection Findings** [GxP Compliance](https://blog.pqegroup.com/tag/gxp-compliance) ## ABSTRACT To ensure compliance and uphold product quality, pharmaceutical companies must stay updated on the latest trends and regulations. A crucial aspect of this is familiarizing themselves with the key inspection findings from regulatory bodies like the MHRA (Medicines and Healthcare products Regulatory Agency). The [MHRA's 2019 report](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#MHRA) highlighted the most frequently cited deficiencies in Good Manufacturing Practice (GMP) inspections, organized according to relevant chapters and annexes. These findings encompass various areas including the [pharmaceutical quality system](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#PQS), [documentation practices](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#Docs), [production processes](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#Production), [qualification and validation procedures](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#QAV), [premises and equipment maintenance,](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#Premises) [manufacturing of sterile medicinal products](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#Sterile), handling complaints and [product recalls](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#Recalls), [quality control](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#QC) measures, [computerized systems](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#Computerized), and [outsourced activities](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#Outsorced)[.](https://blog.pqegroup.com/gxp-compliance/mhra-top-10-inspection-findings#Outsorced) By addressing these findings, pharmaceutical companies can strengthen their compliance efforts, mitigate risks, and uphold their reputation as providers of high-quality pharmaceutical products. It is crucial for companies to proactively identify areas for improvement and implement appropriate measures to rectify these findings. This ensures that their products meet regulatory requirements and continue to be perceived as trustworthy within the industry.    As the pharma industry continues to evolve, it is important for companies to stay updated on the latest trends and regulations in order to ensure compliance and maintain a high level of quality in their products. One key aspect of this is understanding the top inspection findings from regulatory bodies such as the MHRA. In **2019**, the **MHRA** released their annual report detailing the **top 10 most-cited GMP inspection deficiencies by Annex/Chapter**. In this article, we will take a closer look at these findings and provide insights on how companies can improve their compliance with these regulations.  *References by Chapter & Annex – MHRA Report 2019 * ![MHRA Top 10_Graphic Article_ID1384](https://blog.pqegroup.com/hs-fs/hubfs/MHRA%20Top%2010_Graphic%20Article_ID1384.jpg?width=1681&height=621&name=MHRA%20Top%2010_Graphic%20Article_ID1384.jpg) According to the graph sourced from MHRA's annual GMP inspection deficiencies report for 2019, the top 10 most cited deficiencies were:     **1. Chapter 1 - Pharmaceutical Quality System**   The most-cited finding in 2019 appeared in Chapter 1, which covers the requirements for a pharmaceutical quality system. The main issues identified were related to the **implementation and effectiveness of the quality system**, including the **identification and management of risks**. To address these findings, companies should ensure that they have a robust quality system in place, with appropriate documentation and procedures to manage risks and ensure compliance with GMP requirements.  **2. Chapter 4 - Documentation**   Chapter 4 outlines the requirements for documentation, and contained the second most-cited finding in 2019. The main issues identified were related to the **completeness and accuracy of documentation**, including batch records, validation protocols, and standard operating procedures. Companies can improve their compliance with this chapter by ensuring that their documentation is complete, accurate, and up-to-date, with appropriate controls in place for document revision and change management.  **3. Chapter 5 - Production**   Chapter 5 outlines the requirements for production activities, and contained the third most-cited finding in 2019. The main issues identified were related to the **validation of production processes and the control of critical process parameters**. Companies can address these findings by ensuring that they have appropriate validation protocols in place for their production processes, and that critical process parameters are monitored and controlled in accordance with GMP requirements.  **5. Annex 15 - Qualification and Validation**   Annex 15 outlines the requirements for qualification and validation, and was the fourth most-cited finding in 2019. The main issues identified were related to the **completeness and effectiveness of the company's validation activities, including the validation of computerized systems**. Companies can address these findings by ensuring that they have appropriate validation protocols in place for their processes and systems, and that they regularly review and update these protocols as needed to ensure ongoing compliance.  **6. Chapter 3 - Premises and Equipment**   The sixth most-cited finding in 2019 was related to Chapter 3, which covers the requirements for premises and equipment. The main issues identified were related to the **maintenance and qualification of equipmen**t, as well as the **cleanliness and condition of facilities**. To address these findings, companies should ensure that their equipment is properly maintained and qualified, with appropriate documentation and validation records. In addition, facilities should be regularly cleaned and maintained to ensure that they meet GMP requirements.  **7. Annex 1 - Manufacture of Sterile Medicinal Products**   The top findings in 2019 related to Annex 1 outline the requirements for the manufacture of sterile medicinal products. The main issues identified were related to the **design and operation of clean rooms** and associated facilities. Companies can improve their compliance with this Annex by ensuring that they have effective control measures in place for their clean rooms, including appropriate environmental monitoring, cleaning procedures, and staff training.  **9. Chapter 8 - Complaints and Product Recall**   Chapter 8 covers the requirements for handling complaints and product recalls, and had the seventh most-cited finding in 2019. The main issues identified were related to the **timeliness and effectiveness of the company's recall procedures**, as well as the **investigation and management of complaints**. Companies can address these findings by ensuring that they have robust procedures in place for handling complaints and product recalls, including effective communication with regulatory bodies and customers.  **10. Chapter 6 - Quality Control**  Chapter 6 covers the requirements for quality control, and had the eighth most-cited finding in 2019. The main issues identified were related to the **qualification and training of personnel involved in quality control activities**, as well as the **effectiveness of the quality control system**. Companies can address these findings by ensuring that their quality control personnel are properly qualified and trained, and that they have appropriate procedures in place to manage their quality control activities.  **11. Annex 11 – Computerized Systems**  Annex 11 was the ninth most-cited finding in the MHRA's 2019 report. The main issues identified were related to the **validation and control of computerized systems**, including **data integrity and security**. Companies can improve their compliance with this Annex by ensuring that they have appropriate procedures in place for the validation, control, and maintenance of computerized systems. This includes **implementing controls to ensure data integrity, such as access controls, audit trails, and data backup and recovery procedures**. Companies should also ensure that their computerized systems are validated in accordance with GMP requirements and that appropriate change control procedures are in place to manage any changes to these systems.  **12. Chapter 7 - Outsourced Activities**   Chapter 7 outlines the requirements for outsourced activities, which was the ninth most-cited finding in 2019. The main issues identified were related to the **oversight and management of outsourced activities**, including the **selection and qualification of suppliers**. Companies can improve their compliance with this Chapter by ensuring that they have appropriate processes in place for selecting and qualifying suppliers, and that they have effective oversight mechanisms in place to monitor the performance of their outsourced activities.  **Final thoughts**  Staying up-to-date on the latest regulatory requirements and inspection findings is critical for companies in the pharma industry to maintain compliance and ensure the quality of their products. By focusing on the top findings from the MHRA's 2019 report, companies can identify areas for improvement and implement measures to address these findings. This can help companies to avoid costly compliance issues and maintain their reputation as a trusted provider of high-quality pharmaceutical products.  At PQE, we provide expert consulting services to support pharmaceutical companies in achieving and maintaining compliance with regulatory requirements. Our team of highly experienced professionals can help companies assess their current quality management systems, identify gaps, and develop effective strategies for improvement. We also provide training and guidance to help companies stay up-to-date with the latest regulatory developments and industry trends.  With our support, companies can address the top ten MHRA inspection findings and ensure compliance with GMP regulations, while maintaining their focus on innovation and growth. Contact us today to learn more about how we can help your company achieve regulatory compliance and improve its overall quality management system.  [**Download the e-book **](https://focus.pqegroup.com/en/csv-data-integrity/mhra-report) ![MHRA Top Pre Pandemic_Site Banner](https://blog.pqegroup.com/hubfs/MHRA%20Top%20Pre%20Pandemic_Site%20Banner.jpg) ## Do you need support? Check out our [Regulatory Affairs page](https://www2.pqegroup.com/regulatory-affairs/) and[Quality Compliance](https://www2.pqegroup.com/quality-compliance/) Services, and contact our team to request a meeting with our experts. [Connect with us](https://www2.pqegroup.com/contact-us/) #### More on this topic [GxP Compliance ![The FDA Guide to AI in Drug Development](https://blog.pqegroup.com/hubfs/FDA%20guidance%20on%20AI_Blog.webp)](https://blog.pqegroup.com/gxp-compliance/the-fda-guide-to-ai-in-drug-development) 30 Jun 2026 ## [The FDA Guide to AI in Drug Development Read more about how the FDA is redefining AI in drug development from regulatory guidance to compliance expectations.](https://blog.pqegroup.com/gxp-compliance/the-fda-guide-to-ai-in-drug-development) [GxP Compliance ![Why Your Path to Sustainability Should Start With ESG](https://blog.pqegroup.com/hubfs/Path%20to%20Sustainability%20ESG_Blog-2.webp)](https://blog.pqegroup.com/gxp-compliance/why-your-path-to-sustainability-should-start-with-environmental-social-and-governance-esg) 09 Jun 2026 ## [Why Your Path to Sustainability Should Start With ESG ESG is reshaping the pharmaceutical industry, discover how new regulations are driving transparency, compliance, and sustainable growth.](https://blog.pqegroup.com/gxp-compliance/why-your-path-to-sustainability-should-start-with-environmental-social-and-governance-esg) [GxP Compliance ![CSA Validation Strategies in SAP S/4HANA®](https://blog.pqegroup.com/hubfs/CSA%20SAP%204%20HANA_Blog-2.webp)](https://blog.pqegroup.com/gxp-compliance/csa-validation-strategies-in-sap-s/4hana) 27 May 2026 ## [CSA Validation Strategies in SAP S/4HANA® Discover CSA in SAP S/4HANA validation and its digital approach focused on risk and efficiency.](https://blog.pqegroup.com/gxp-compliance/csa-validation-strategies-in-sap-s/4hana) ![new PQE logo white tagline](https://blog.pqegroup.com/hubfs/new%20PQE%20logo%20white%20tagline.png) ISO 9001 Certified compliance services provider since 1998.   ![Logo ISO 9001](https://blog.pqegroup.com/hs-fs/hubfs/Logo%20ISO%209001.png?width=125&name=Logo%20ISO%209001.png)   - Discover PQE - [Work with PQE](https://www2.pqegroup.com/careers/) - [Locations](https://www2.pqegroup.com/contact-us/#locations) - [About](https://www2.pqegroup.com/about/) - [Blog](https://blog.pqegroup.com/) - Useful Links - [Privacy Notice](https://www2.pqegroup.com/privacy-notice/) - [Cookie Policy](https://www2.pqegroup.com/cookie-policy/) - [Model of Organization](https://www2.pqegroup.com/model-of-organization/) - [Ethical Code](https://www2.pqegroup.com/ethical-code/) English CHANGE LANGUAGE Copyright **2024** | Proudly powered by **PQE Group Creative Team** [LinkedIn](https://www.linkedin.com/company/pqe-group) [![twitter](https://blog.pqegroup.com/hubfs/twitter-w.png) Twitter](https://twitter.com/PQEGroup) [Facebook](https://www.facebook.com/PQEGroup/) [Instagram](https://www.instagram.com/lifeatpqe) [YouTube](https://www.youtube.com/c/PQEGroup) [Xing](https://www.xing.com/pages/pqegroup)